East Coast Asset Management Has Trimmed Schlumberger LTD (SLB) Position By $1.25 Million; Last Week Allergan plc (AGN) Analysts

February 15, 2018 - By Marguerite Chambers

East Coast Asset Management Llc decreased Schlumberger Ltd (SLB) stake by 52.7% reported in 2017Q3 SEC filing. East Coast Asset Management Llc sold 18,079 shares as Schlumberger Ltd (SLB)’s stock declined 11.04%. The East Coast Asset Management Llc holds 16,228 shares with $1.13M value, down from 34,307 last quarter. Schlumberger Ltd now has $90.98B valuation. The stock decreased 0.20% or $0.13 during the last trading session, reaching $65.74. About 5.79M shares traded. Schlumberger Limited (NYSE:SLB) has declined 3.30% since February 15, 2017 and is downtrending. It has underperformed by 20.00% the S&P500.

Among 27 analysts covering Allergan Inc. (NYSE:AGN), 19 have Buy rating, 0 Sell and 8 Hold. Therefore 70% are positive. Allergan Inc. had 109 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Hold” rating by Cantor Fitzgerald on Tuesday, July 18. The stock of Allergan plc (NYSE:AGN) earned “Buy” rating by Cowen & Co on Tuesday, October 10. The rating was downgraded by Mizuho on Wednesday, April 6 to “Neutral”. RBC Capital Markets maintained Allergan plc (NYSE:AGN) on Thursday, January 4 with “Buy” rating. The rating was initiated by Guggenheim with “Neutral” on Monday, April 18. The company was maintained on Sunday, August 9 by Canaccord Genuity. Deutsche Bank maintained Allergan plc (NYSE:AGN) rating on Tuesday, August 9. Deutsche Bank has “Buy” rating and $278 target. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, December 6 report. Leerink Swann maintained it with “Buy” rating and $242.0 target in Wednesday, February 7 report. The stock has “Buy” rating by RBC Capital Markets on Thursday, October 19. See Allergan plc (NYSE:AGN) latest ratings:

07/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $214 New Target: $215 Maintain
07/02/2018 Broker: Leerink Swann Rating: Buy New Target: $242.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $208 New Target: $215 Maintain
06/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $171.0 Maintain
06/02/2018 Broker: Mizuho Rating: Hold New Target: $185.0 Maintain
29/01/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Overweight Upgrade
23/01/2018 Broker: Mizuho Rating: Hold New Target: $185.0 Maintain
17/01/2018 Broker: Susquehanna Rating: Hold New Target: $195.0 Maintain
10/01/2018 Broker: UBS Rating: Buy New Target: $250.0 Maintain
04/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $218.0 Maintain

The stock decreased 2.00% or $3.33 during the last trading session, reaching $163.3. About 2.07M shares traded. Allergan plc (NYSE:AGN) has declined 3.42% since February 15, 2017 and is downtrending. It has underperformed by 20.12% the S&P500.

Investors sentiment decreased to 0.33 in 2017 Q3. Its down 0.05, from 0.38 in 2017Q2. It fall, as 3 investors sold Allergan plc shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 54,287 shares or 4.93% less from 57,100 shares in 2017Q2 were reported. Rech Mngmt has 0% invested in Allergan plc (NYSE:AGN). Connors Investor Service has 0.03% invested in Allergan plc (NYSE:AGN) for 1,000 shares. 3,975 were reported by Mitchell Mcleod Pugh And Williams Inc. Gemmer Asset Mgmt Ltd Llc accumulated 116 shares or 0.01% of the stock. Grassi Management holds 0.24% in Allergan plc (NYSE:AGN) or 6,825 shares. Cubic Asset Mgmt Lc reported 0.13% in Allergan plc (NYSE:AGN). Eqis Cap Management Inc has invested 0.09% in Allergan plc (NYSE:AGN). Frontier Investment Mngmt holds 30,139 shares or 0.51% of its portfolio. California-based Dowling Yahnke Ltd Company has invested 0.04% in Allergan plc (NYSE:AGN).

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.31 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

Among 38 analysts covering Schlumberger Limited. (NYSE:SLB), 31 have Buy rating, 1 Sell and 6 Hold. Therefore 82% are positive. Schlumberger Limited. had 139 analyst reports since July 22, 2015 according to SRatingsIntel. On Thursday, September 3 the stock rating was maintained by HSBC with “Buy”. DA Davidson initiated the shares of SLB in report on Friday, February 19 with “Buy” rating. The stock of Schlumberger Limited (NYSE:SLB) earned “Buy” rating by Evercore on Saturday, August 22. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, June 21. BMO Capital Markets maintained Schlumberger Limited (NYSE:SLB) rating on Friday, September 4. BMO Capital Markets has “Outperform” rating and $105.0 target. The stock of Schlumberger Limited (NYSE:SLB) earned “Equal Weight” rating by Barclays Capital on Monday, January 25. BMO Capital Markets downgraded Schlumberger Limited (NYSE:SLB) on Wednesday, October 11 to “Market Perform” rating. The firm earned “Buy” rating on Tuesday, January 16 by RBC Capital Markets. The firm earned “Buy” rating on Monday, April 4 by Goldman Sachs. The stock has “Hold” rating by Jefferies on Monday, April 25.

Investors sentiment is 0.88 in Q3 2017. Its the same as in 2017Q2. It is flat, as 69 investors sold SLB shares while 596 reduced holdings. only 105 funds opened positions while 481 raised stakes. 1.20 billion shares or 11.55% more from 1.07 billion shares in 2017Q2 were reported. Moreover, Keybank Association Oh has 0.26% invested in Schlumberger Limited (NYSE:SLB). 489,453 are owned by Becker Mgmt. Bb&T stated it has 0.33% in Schlumberger Limited (NYSE:SLB). 5,120 were reported by Pro Incorporated. The Ontario – Canada-based Cumberland Partners Limited has invested 0.12% in Schlumberger Limited (NYSE:SLB). J Goldman And Limited Partnership has 0.21% invested in Schlumberger Limited (NYSE:SLB) for 60,262 shares. Hirtle Callaghan Co Ltd Liability Co, Pennsylvania-based fund reported 2,320 shares. Thompson Siegel & Walmsley Ltd Llc owns 0.04% invested in Schlumberger Limited (NYSE:SLB) for 43,553 shares. Macguire Cheswick And Tuttle Investment Counsel Ltd Llc holds 2.15% or 156,746 shares in its portfolio. Coastline accumulated 21,357 shares. Farr Miller & Washington Ltd Liability Corporation Dc invested in 291,184 shares or 1.94% of the stock. 1St Source National Bank accumulated 53,401 shares. Atria Invs Lc has invested 0.09% in Schlumberger Limited (NYSE:SLB). 32,780 were reported by Braun Stacey Associate Inc. Chase Counsel owns 3,250 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: